Company Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics.
The company’s pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy.
The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 391 |
| CEO | Sarah Boyce |
Contact Details
Address: 10578 Science Center Drive, Suite 125 San Diego, California 92121 United States | |
| Phone | 858 401 7900 |
| Website | aviditybiosciences.com |
Stock Details
| Ticker Symbol | RNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001574111 |
| CUSIP Number | 05370A108 |
| ISIN Number | US05370A1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sarah Boyce | President, Chief Executive Officer and Director |
| Dr. Troy Edward Wilson J.D., Ph.D. | Co-Founder and Independent Chairman |
| Dr. W. Michael F. Flanagan Ph.D. | Chief Scientific Officer |
| John B. Moriarty Jr., ESQ., J.D. | Chief Legal Officer and Corporate Secretary |
| Teresa McCarthy | Chief Human Resources Officer |
| Prof. Mark E. Davis Ph.D. | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers |
| Dr. Frank P. McCormick Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Charles Calderaro III | Chief Technical Officer |
| Eric B. Mosbrooker | Chief Commercial Officer |
| Kathleen Gallagher | Chief Program Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 16, 2016 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2016 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 8, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 30, 2015 | 20-F | Annual and transition report of foreign private issuers |
| Mar 23, 2015 | 15-12B | Securities registration termination |
| Feb 17, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2015 | 6-K | Report of foreign issuer |
| Feb 12, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 11, 2015 | 25 | Filing |
| Feb 10, 2015 | 6-K | Report of foreign issuer |